Issue 23, 2014

Engineered nanoparticles: thrombotic events in cancer

Abstract

Engineered nanoparticles are being increasingly produced for specific applications in medicine. Broad selections of nano-sized constructs have been developed for applications in diagnosis, imaging, and drug delivery. Nanoparticles as contrast agents enable conjugation with molecular markers which are essential for designing effective diagnostic and therapeutic strategies. Such investigations can also lead to a better understanding of disease mechanisms such as cancer-associated thrombosis which remains unpredictable with serious bleeding complications and high risk of death. Here we review the recent and current applications of engineered nanoparticles in diagnosis and therapeutic strategies, noting their toxicity in relation to specific markers as a target.

Graphical abstract: Engineered nanoparticles: thrombotic events in cancer

Article information

Article type
Minireview
Submitted
21 Aug 2014
Accepted
24 Sep 2014
First published
25 Sep 2014

Nanoscale, 2014,6, 14141-14152

Engineered nanoparticles: thrombotic events in cancer

A. M. E. Abdalla, L. Xiao, C. Ouyang and G. Yang, Nanoscale, 2014, 6, 14141 DOI: 10.1039/C4NR04825C

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements